American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Valion Bio, Inc.
$2.4MMarket cap
$780.0KRevenue · FY2024
-$8.9MNet income
52Employees
VBIONASDAQ
2021IPO
About Valion Bio, Inc.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2024
- $780.0K
- Net income
- -$8.9M
- Total assets
- $31.6M
- Market cap
- $2.4M
Source: SEC EDGAR · updated Jun 8, 2026
- Market cap
- $2.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 11, 2021
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Valion Bio, Inc..
Write a review
Explore
Browse all →
